The Role of Gemcitabine in First-Line Treatment of Advanced Ovarian Carcinoma
Author:
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 26-32
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group studyGynecologic Oncology, 2003
- Docetaxel for Patients With Paclitaxel-Resistant Müllerian CarcinomaJournal of Clinical Oncology, 2000
- ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 1998
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal of Cancer, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI: Journal of the National Cancer Institute, 1995
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI: Journal of the National Cancer Institute, 1994
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group studyCancer, 1986